CHF70.62 ABBN.SW ABB SIX pre-market most active 25 Feb 2026: watch CHF88 upside
Pre-market: ABBN.SW stock at CHF70.62 on 25 Feb 2026 with heavy volume and a Meyka AI three-year CHF88 forecast
-
-
Pre-mkt 25 Feb: 3110.T Nitto Boseki JPX up 23.58% to JPY 26,200.00: watch breakout
3110.T stock jumps 23.58% pre-market to JPY 26,200.00 on volume; see Meyka AI grade, technicals, and forecast for trade setup
-
HK$1.99 pre-market 25 Feb 2026: 9977.HK Shandong Fengxiang (HKSE) oversold bounce, key resistance HK$2.40
Pre-market: 9977.HK stock at HK$1.99 shows an oversold bounce; Meyka AI one-year forecast HK$2.94, upside 47.75%
-
MBQ.DE Mobotix AG (XETRA) +38% pre-market 25 Feb 2026: key targets to watch
MBQ.DE stock jumps 38% pre-market on heavy volume; technicals and Meyka AI forecast and grade included
-
Hong Kong ESF Bribery: 14 Convicted; ICAC Signals Tighter Oversight February 25
ESF bribery case: 14 convicted in Hong Kong as ICAC signals tighter oversight of school admissions. What this means for Hong Kong education, compliance, and sector risks.
-
Top gainer LS9.SI Leader Environmental (SES) +10.00% pre-market 25 Feb 2026: volume spike signals trading interest
LS9.SI stock rises 10.00% pre-market on 25 Feb 2026 with volume 13,887,100. Meyka AI analysis and forecast included
-
^DJI Today: February 25 China Curbs Japan Dual-Use Exports; Risk-Off Watch
China Japan export controls add 20 entities to a banned list and 20 to a watchlist. Japan defense stocks ease as yen slides to ¥155.27. Rare earth risk and ^DJI watch.
-
Down 20% intraday: BPH.AX BPH Energy Limited (ASX) earnings 25 Feb 2026, guidance key
Intraday earnings spotlight on BPH.AX stock: shares -20% as BPH Energy Limited reports on 25 Feb 2026. Key metrics, forecast and outlook
-
TLKMF $0.22 on 24 Feb 2026: Telkom Indonesia Perusahaan Perseroan (PNK) outlook
TLKMF stock rises to $0.22 on 24 Feb 2026; Meyka AI forecast, grade and short-term outlook for TLKMF stock
-
Barclays Maintains Overweight on Vir Biotechnology, Inc. (VIR) Feb 24 2026
Barclays maintains Overweight on Vir Biotechnology (VIR) and raises target to $30. VIR analyst rating Feb 24 2026
